InvestSMART

Clinuvel Pharmaceuticals Limited (ASX: CUV) - Announcements

Current share price for CUV : $7.380 0.08 (1.07%)+

ASX company news and announcements for Clinuvel Pharmaceuticals Limited (CUV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clinuvel Pharmaceuticals Limited (CUV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clinuvel Pharmaceuticals Limited (CUV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clinuvel Pharmaceuticals Limited (CUV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$373 Becoming a substantial holder 10 Aug 2016 6:20PM $4.970 $7.380 risen by 48.49%
$373 Becoming a substantial holder 10 Aug 2016 5:20PM $4.970 $7.380 risen by 48.49%
$373 Change of Director's Interest Notice x 4 5 Aug 2016 4:37PM $5.030 $7.380 risen by 46.72%
$373 Appendix 3B 4 Aug 2016 5:12PM $5.000 $7.380 risen by 47.60%
$373 Clinuvel completes combination therapy pre-clinical study 3 Aug 2016 9:54AM $5.090 $7.380 risen by 44.99%
$373 Appendix 4C - quarterly 29 Jul 2016 9:38AM $4.750 $7.380 risen by 55.37%
$373 FDA accept SCENESSE clinical data package for NDA submission 18 Jul 2016 10:03AM $4.990 $7.380 risen by 47.90%
$373 FDA awards SCENESSE Fast Track designation for EPP treatment 6 Jul 2016 8:26AM $4.400 $7.380 risen by 67.73%
$373 SCENESSE launched in Europe 22 Jun 2016 10:14AM $4.080 $7.380 risen by 80.88%
$373 Clinuvel joins Nasdaq international Designation 2 Jun 2016 8:24AM $4.700 $7.380 risen by 57.02%
$373 SCENESSE Treatment in Europe 18 May 2016 11:10AM $4.800 $7.380 risen by 53.75%
$373 Appendix 4C - quarterly 29 Apr 2016 8:24AM $4.300 $7.380 risen by 71.63%
$373 Change in substantial holding 11 Apr 2016 9:50AM $4.080 $7.380 risen by 80.88%
$373 Clinuvel Newsletter 5 Apr 2016 12:40PM $4.010 $7.380 risen by 84.04%
$373 NICE Highly Specialised Technology workshop reviews SCENESSE 24 Mar 2016 9:49AM $4.160 $7.380 risen by 77.40%
$373 s.708A Notice 18 Mar 2016 9:37AM $3.500 $7.380 risen by 110.86%
$373 Appendix 3B 18 Mar 2016 9:34AM $3.500 $7.380 risen by 110.86%
$373 Change in substantial holding 18 Mar 2016 8:21AM $3.500 $7.380 risen by 110.86%
$373 Change in substantial holding 15 Mar 2016 11:00AM $3.300 $7.380 risen by 123.64%
$373 Clinuvel accredits first European EPP expert centres 15 Mar 2016 10:35AM $3.300 $7.380 risen by 123.64%
$373 Clinuvel Placement 15 Mar 2016 9:56AM $3.300 $7.380 risen by 123.64%
$373 Trading Halt 11 Mar 2016 9:35AM $3.300 $7.380 risen by 123.64%
$373 Appendix 4D and Half Year Report 19 Feb 2016 11:22AM $3.060 $7.380 risen by 141.18%
$373 Clinuvel brief on European commercialisation 16 Feb 2016 10:16AM $3.050 $7.380 risen by 141.97%
$373 US FDA orphan designation received for cutaneous porphyrias 12 Feb 2016 8:58AM $3.000 $7.380 risen by 146%

651 - 675 of 881 results

Page 27 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.